Rubius Therapeutics, Inc. (RUBY) financial statements (2020 and earlier)

Company profile

Business Address 399 BINNEY STREET, SUITE 300
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments283404
Cash and cash equivalents92307
Short-term investments19197
Restricted cash and investments 1
Other undisclosed current assets610
Total current assets:289414
Noncurrent Assets
Operating lease, right-of-use asset47
Property, plant and equipment5763
Restricted cash and investments22
Other noncurrent assets00
Total noncurrent assets:10665
TOTAL ASSETS:395479
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities138
Accounts payable78
Accrued liabilities0 
Employee-related liabilities5 
Interest and dividends payable0 
Debt11 
Other undisclosed current liabilities1012
Total current liabilities:3420
Noncurrent Liabilities
Long-term debt and lease obligation8666
Long-term debt, excluding current maturities5024
Capital lease obligations41
Operating lease, liability37
Liabilities, other than long-term debt00
Deferred rent credit 0
Other liabilities0 
Other undisclosed noncurrent liabilities 0
Total noncurrent liabilities:8766
Total liabilities:12186
Stockholders' equity
Stockholders' equity attributable to parent274393
Common stock00
Additional paid in capital587543
Accumulated other comprehensive income (loss)0(0)
Accumulated deficit(313)(150)
Total stockholders' equity:274393
TOTAL LIABILITIES AND EQUITY:395479

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:1 
Operating expenses(170)(92)
Other undisclosed operating loss(1) 
Operating loss:(170)(92)
Nonoperating income62
Investment income, nonoperating80
Interest and debt expense(3)(0)
Loss before gain (loss) on sale of properties:(166)(90)
Other undisclosed net income30
Net loss available to common stockholders, diluted:(163)(89)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(163)(89)
Comprehensive loss:(163)(89)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)
Comprehensive loss, net of tax, attributable to parent:(163)(89)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: